Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 246 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Keratosis, Actinic Clear all
Completed Not applicable Interventional

Indoor Daylight Photo Dynamic Therapy for Actinic Keratosis

NCT03805737
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Amulez and sunlight, Amulez and red light treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jun 25, 2026, 10:47 AM EDT
Completed No phase listed Observational

Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers

NCT01971957
View directory record Official record
Conditions
Sjogren-Larsson Syndrome (SLS)
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 4 Interventional

Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents

NCT03279328
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Topical Steroid Ointment, Vaseline, Skin Barrier Moisturier
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jun 25, 2026, 10:47 AM EDT
Active, not recruiting Not applicable Interventional

Microwave Treatment for Actinic Keratosis

NCT05636800
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Swift System
Device
Lead sponsor
Blackwell Device Consulting
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Results available

An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses

NCT04549792
View directory record Official record
Conditions
Ichthyosis
Interventions
Ustekinumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
No Longer Available No phase listed Expanded access

"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"

NCT04825613
View directory record Official record
Conditions
Primary Lateral Sclerosis, Adult, 1
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Zinc Bioavailability From Amaranth-enriched Maize Tortillas

NCT02208609
View directory record Official record
Conditions
Nutritional Deficiency
Interventions
Day 1: Maize Tortillas with 20% Amaranth, Day 2 Maize Tortillas without 20% Amaranth
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Months to 36 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Phase 1 Interventional

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum

NCT07401277
View directory record Official record
Conditions
Actinic Keratoses
Interventions
5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

NCT02424305
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel 0.018%, LEO 43204 gel 0.1%, LEO 43204 gel 0.037%
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

NCT02864082
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%
Drug
Lead sponsor
Patagonia Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

The CO2RE® System for Vulvar Lichen Sclerosus

NCT04148651
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
The CO2RE® System
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jun 25, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

NCT04697056
View directory record Official record
Conditions
Ichthyosis
Interventions
Imsidolimab, placebo
Drug · Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Terminated No phase listed Observational

Comparing Immune Responses to Topical Imiquimod

NCT04809662
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Imiquimod
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population

NCT01016106
View directory record Official record
Conditions
Atopic Dermatitis, Ichthyosis Vulgaris
Interventions
Buccal Swab
Genetic
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Study of SOR007 Ointment for Actinic Keratosis

NCT03083470
View directory record Official record
Conditions
Actinic Keratosis
Interventions
SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
Drug · Other
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
45 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00700063
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Topical Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Hot Springs, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Phase 3 Interventional

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

NCT06851507
View directory record Official record
Conditions
Multiple Actinic Keratoses
Interventions
Fluorouracil 5-FU, Fluorouracil/Calcipotriene
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

NCT00208026
View directory record Official record
Conditions
Netherton Syndrome
Interventions
Pimecrolimus 1% Cream
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jun 25, 2026, 10:47 AM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption of Zinc (Zn) From Zn-biofortified and Zn-fortified Maize in Young Zambian Children Between 24-36 Months

NCT02208635
View directory record Official record
Conditions
Nutritional Deficiency
Interventions
Biofortified Maize, Fortified Maize, Control Maize
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
24 Months to 36 Months
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy in Treating Patients With Skin Cancer

NCT00002975
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous Condition
Interventions
aminolevulinic acid
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

NCT06778434
View directory record Official record
Conditions
Actinic Keratosis, Imipramine, Photodynamic Therapy
Interventions
Imipramine, Control Vehicle
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

NCT04319159
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jun 25, 2026, 10:47 AM EDT